triple agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-03. Anything still debated is marked as such rather than presented as settled.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Chester Fisher died in 1965 at age 84. His sons maintained leadership of the company, with Aiken becoming Chairman and Benjamin becoming president. The youngest son, James Fisher, had the title Senior Vice President. Fisher Scientific Company issued its first public stock in 1965, and that year the company had $58 million in sales and close to a million customer transactions. In 1968 Fisher shares were listed on the New York Stock Exchange. In 1965 the company introduced the Differential Thermalyzer, a differential thermal analysis instrument. It acquired Pfeiffer Glass, Inc. in 1966, a manufacturer of high accuracy volumetric pipettes. The company released the Photometric Titralyzer that year, and a Hem-alyzer in 1968. In 1968, it purchased Massachusetts-based Jarrell-Ash Company, a producer of optical instrumentation, particularly for emission and atomic absorption spectroscopy. It acquired Chicago-based Stansi Scientific Company in 1967, expanding into educational science supplies. In 1976, Fisher Scientific established an Instrument Service Division. Fisher was acquired by Morristown, New Jersey–based Allied Corporation in 1981 for $330 million. At this time Benjamin R. Fisher was Chairman of the company, having gained the position in 1975 upon Aiken's retirement. Operating as a subsidiary of Allied Corporation (and later AlliedSignal Inc., and The Henley Group), Fisher established a Biotechnology Division in 1985. In 1991, The Henley Group sold a majority interest in Fisher through a public stock offering.
== History == Pentazocine was developed by the Sterling Drug Company, Sterling-Winthrop Research Institute, of Rensselaer, New York. The analgesic compound was first made at Sterling in 1958. U.S. testing was conducted between 1961 and 1967. It was approved by the Food and Drug Administration in June 1967 after being favorably reviewed following testing on 12,000 patients in the United States. By mid 1967 Pentazocine was already being sold in Mexico, England, and Argentina, under different trade names.
=== Generic forms === Generic forms of oral selegiline are available in the United States. However, generic forms of the orally disintegrating tablet and the transdermal patch are not available in this country. The latter formulations of selegiline are very expensive, and this can be prohibitive to their use. There has been poor insurance coverage of the transdermal patch form for depression, with insurance companies often requiring patients to first fail to respond to one or two other antidepressants and to be responsible for larger copayments. It is expected that generics of the transdermal patch will become available at some point in the future.
Sources: en.wikipedia.org
=== Flexible linkers === Turns are sometimes found within flexible linkers or loops connecting protein domains. Linker sequences vary in length and are typically rich in polar uncharged amino acids. Flexible linkers allow connecting domains to freely twist and rotate to recruit their binding partners via protein domain dynamics. They also allow their binding partners to induce larger scale conformational changes by long-range allostery.
The first 7-Eleven store to open in Canada was in Calgary, Alberta, on June 29, 1969. There are 562 7-Eleven stores in Canada as of December 2022. Winnipeg, Manitoba, has the world's largest number of Slurpee consumers, with an estimated 1,500,000 Slurpees sold since the first 7-Eleven opened on March 21, 1970. All 7-Eleven locations in Canada are corporate operated. Like its U.S. counterparts every July 11 the stores offer free Slurpees on "7-Eleven Day". Many 7-Eleven locations offer petrol stations, either supplied by national distributors such as Imperial Oil and Petro-Canada, or under private label 7-Eleven branding. In March 2016, 7-Eleven acquired 148 Esso stations in Alberta and British Columbia from Imperial Oil for C$2.8 billion, with many of their convenience stores being converted to 7-Eleven. Some locations were not converted, and operate under the banner "smartstop 24/7" with their existing store formats, typically inherited from On the Run. In April 2025, 7-Eleven announced that it would convert its remaining 7-Eleven-branded petrol stations in Alberta and Ontario to either Esso, Mobil, or Petro-Canada. In November 2005, 7-Eleven started offering the Speak Out Wireless cellphone service in Canada. 7-Eleven locations also featured CIBC ATMs—in June 2012, these machines were replaced with ATMs operated by Scotiabank. 7-Eleven abandoned the Ottawa, Ontario, market in December 2009 after selling its six outlets to Quickie Convenience Stores, a regional chain.
== Cultivation == Cut flower cultivation is intensive, usually on the basis of greenhouse monocultures, and requires large amounts of highly toxic pesticides, residues of which can often still be found in flower shops on imported flowers. As with the production of fruit and vegetables, the industry depends on significant amounts of water, which may be collected and stored by the farm owners. The Patel Dam failure in May 2018, associated with a large Kenyan rose farm, killed dozens of people. These facts have spurred the development of movements like "Slow Flowers", which propagates sustainable floriculture in the consumer country (US, Canada) itself.
Sources: en.wikipedia.org
Stachys affinis, commonly called crosne, Chinese artichoke, Japanese artichoke, knotroot, or artichoke betony, is a perennial herbaceous plant of the family Lamiaceae, originating from China. Its rhizome is a root vegetable that can be eaten raw, pickled, dried or cooked.
Sports drinks, also known as electrolyte drinks, are non-caffeinated functional beverages whose stated purpose is to help athletes replace water, electrolytes, and energy before, during and especially after training or competition. The evidence is lacking pertaining to the efficacy of use of commercial sports drinks for sports and fitness performance.
"Catholic conservatives in the Weimar Republic: the politics of the Rhenish-Westphalian aristocracy, 1918–1933." German History 18.1 (2000): 60-85. Kohler, Eric D. "The Successful German Center-Left: Joseph Hess and the Prussian Center Party, 1908–32." Central European History 23.4 (1990): 313-348. Lutz, Ralph Haswell. "The Collapse of German Democracy under the Brüning Government March 30, 1930–May 30, 1932." Pacific Historical Review (1941) 10#1: 1-14. online Ross, Ronald J. "Critic of the Bismarckian Constitution: Ludwig Windthorst and the Relationship Between Church and State in Imperial Germany," Journal of Church & State (1979) 21#3 pp 483–506. online Ross, Ronald J. Beleaguered Tower: The Dilemma of Political Catholicism in Wilhelmine Germany (1976), Zeender, John. "Ludwig Windthorst, 1812-1891," History (1992) 77#290 pp 237–54 online Zeender, John K. "The German Center Party, 1890-1906." Transactions of the American Philosophical Society (1976) 66#1 pp 1–125.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。